Recently, an open-label randomized 12-month trial (the Mechanisms of Erythropoietin Action in the Cardiorenal Syndrome [EPOCARES]) had been designed to discern hematopoietic from nonhematopoietic effects of EPO in patients with the combination of chronic heart failure and chronic kidney disease and mild anemia [83]. Here, EPO is linked to congestive heart failure.